Sebastian Mathea

Max Von Laue Str. 15
Frankfurt Am Main, HE 60438, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

The structural basis for LRRK2's activation and autoinhibition.

The structural basis for LRRK2's activation and autoinhibition.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2026

The structural basis for LRRK2's activation and autoinhibition.

The structural basis for LRRK2's activation and autoinhibition.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2026

Identification and Validation of 3-Cyano-Quinoline Ligands Targeting Integrin-Linked Kinase (ILK).

Identification and Validation of 3-Cyano-Quinoline Ligands Targeting Integrin-Linked Kinase (ILK).

Journal: Journal of medicinal chemistry

Published: May 26, 2026

Discovery and Development of a Potent LIMK2 Isoform-Specific Degrader.

Discovery and Development of a Potent LIMK2 Isoform-Specific Degrader.

Journal: ACS chemical biology

Published: May 01, 2026

The structural basis for LRRK2's activation and autoinhibition.

The structural basis for LRRK2's activation and autoinhibition.

Journal: Cell

Published: November 21, 2025

Structure-Based Design, Synthesis, and Evaluation of Novel Ponatinib Derivatives With a Significantly Altered Selectivity Profile.

Structure-Based Design, Synthesis, and Evaluation of Novel Ponatinib Derivatives With a Significantly Altered Selectivity Profile.

Journal: ChemMedChem

Published: November 07, 2025

Covalent Targeting Leads to the Development of a LIMK1 Isoform-Selective Inhibitor.

Covalent Targeting Leads to the Development of a LIMK1 Isoform-Selective Inhibitor.

Journal: Journal of medicinal chemistry

Published: July 02, 2025

Type II kinase inhibitors that target Parkinson's disease-associated LRRK2.

Type II kinase inhibitors that target Parkinson's disease-associated LRRK2.

Journal: Science advances

Published: June 04, 2025

Selectivity profiles and substrate recognition of Rab-phosphorylating kinases.

Selectivity profiles and substrate recognition of Rab-phosphorylating kinases.

Journal: The Biochemical journal

Published: May 15, 2025

Native Taylor/Non-Taylor Dispersion-Mass Spectrometry (TNT-MS) Allows Rapid Protein Desalting and Multiplexed, Label-Free Ligand Screening.

Native Taylor/Non-Taylor Dispersion-Mass Spectrometry (TNT-MS) Allows Rapid Protein Desalting and Multiplexed, Label-Free Ligand Screening.

Journal: Small methods

Published: April 24, 2025

Repurposing of the RIPK1-Selective Benzo[1,4]oxazepin-4-one Scaffold for the Development of a Type III LIMK1/2 Inhibitor.

Repurposing of the RIPK1-Selective Benzo[1,4]oxazepin-4-one Scaffold for the Development of a Type III LIMK1/2 Inhibitor.

Journal: ACS chemical biology

Published: April 14, 2025

Development of pyrazolo[1,5-a]pyrimidine based macrocyclic kinase inhibitors targeting AAK1.

Development of pyrazolo[1,5-a]pyrimidine based macrocyclic kinase inhibitors targeting AAK1.

Journal: European journal of medicinal chemistry

Published: April 07, 2025

Showing 1-12 of 53

Last Updated: 09/26/2026